Adolescent Access Weighs Heavy In US FDA Decision On First OTC Daily Oral Contraceptive
Executive Summary
FDA asks its Nonprescription Drug and Obstetrics, Reproductive and Urologic Drugs advisory committees during a joint meeting on 9-10 May to recommend whether to approve HRA Pharma’s proposal for OTC switch of a daily oral contraceptive, its 0.075-mg norgestrel tablet branded Opill.
You may also be interested in...
US FDA Advisory Committee Formats Can Spur Unhealthy Dynamics – Califf
FDA commissioner is thinking about how advisory panel interactions might improperly influence meeting outcomes as the agency undertakes a 'stem to stern' review of the process.
US FDA Advisory Committee Formats Can Spur Unhealthy Dynamics – Califf
FDA commissioner is thinking about how advisory panel interactions might improperly influence meeting outcomes as the agency undertakes a 'stem to stern' review of the process.
‘Over-Reporting’ An ‘Inherent Risk’ In Self-Report Study – Oral Contraceptive OTC Switch Sponsor
HRA says its research in support of its sNDA for its 0.75-mg norgestrel tablet branded Opill shows accurate OTC self-selection and safe use of the progestin-only drug by females of reproductive age.